Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

CAR therapies

- PMLiVE

Corcept Therapeutics reports positive phase 3 results in ovarian cancer treatment

The company also plans to expand its phase 2 BELLA study to include three new study arms

- PMLiVE

AbbVie’s Elahere granted MHRA approval to treat platinum-resistant ovarian cancer

Approximately 7,500 people are diagnosed with ovarian cancer every year in the UK

- PMLiVE

Merck shares promising phase 3 results for Keytruda in ovarian cancer

Approximately 20,890 cases of the disease are expected to be diagnosed in the US this year

- PMLiVE

FDA approves Verastem Oncology’s combination therapy for rare ovarian cancer type

Approximately 6,000 to 8,000 women in the US are living with low-grade serous ovarian cancer

- PMLiVE

AbbVie’s Elahere shows consistent survival benefits in late-stage ovarian cancer trial

Approximately 20,000 cases of the disease are diagnosed in the US every year

- PMLiVE

NICE recommends pharmaand’s Rubraca for advanced ovarian cancer

An estimated 7,500 new cases of the disease were diagnosed in the UK between 2017 and 2019

- PMLiVE

Merck shares positive phase 3 results for Keytruda/Lynparza regimen in ovarian cancer

Ovarian cancer is the seventh most common cancer in women globally

- PMLiVE

Genmab to expand oncology portfolio through $1.8bn ProfoundBio acquisition

The deal includes a next-generation ADC being evaluated as a treatment for ovarian cancer and other solid tumours

- PMLiVE

AbbVie’s Elahere granted full FDA approval for previously-treated ovarian cancer

The company recently gained access to the therapy through its $10.1bn acquisition of ImmunoGen

- PMLiVE

AstraZeneca/Merck’s Lynparza combination recommended by NICE for advanced ovarian cancer

Approximately 7,400 new cases of the disease are diagnosed in the UK every year

- PMLiVE

AbbVie to expand solid tumour portfolio with $10bn ImmunoGen acquisition

The agreement grants the company access to FDA-approved ovarian cancer drug Elahere

EU flag

EC approves pharmaand’s Rubraca as advanced ovarian cancer maintenance treatment

An estimated 66,000 new cases of ovarian cancer are diagnosed in Europe each year

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links